In Simple Terms
Brain cancer can be hard to treat because cancer cells spread into healthy tissue, and the brain has a natural barrier that blocks many medicines. Researchers tested a way to briefly open that barrier with focused sound waves and carry tiny gene-targeting molecules into the brain. The approach slowed tumors and helped animals live longer, but it has not been tested as a treatment for people.
A Tumor That Is Hard to Remove and Control
Glioblastoma is the most common malignant brain tumor in adults and one of the most aggressive cancers. It is estimated to kill more than 13,000 people in the United States each year. The challenge is not simply that it forms a visible mass that surgeons can try to remove. Cancer cells can also infiltrate the healthy brain tissue around the tumor.
When tumor cells mingle with brain tissue, surgeons may not be able to see a clear boundary between what should be removed and what must be preserved. Removing every cancer cell can therefore risk damaging healthy parts of the brain. Cells left behind can continue driving the disease, making it difficult to control even after surgery.
Standard treatment usually begins with surgery to remove as much of the tumor as possible. Doctors then use radiation and chemotherapy to target remaining cancer cells and try to extend the patient’s life. These steps do not eliminate the challenges of the disease, however, and they cannot guarantee that cells scattered through the surrounding tissue will be removed. Researchers are therefore interested in approaches that might reach hard-to-access cells or act on several factors that help the tumor persist.
There is another obstacle, separate from the cancer’s spread through the brain: the blood-brain barrier. This natural system separates the blood from brain tissue and helps protect the brain from harmful substances, including toxins and infectious agents. But that same protection can get in the way of treatment, because many medicines cannot cross the barrier in sufficient amounts to reach a tumor.
Small Molecules That Target More Than One Gene
A team at the University of Virginia has proposed an approach that does not rely on a drug aimed at just one process in a cancer cell. The idea centers on molecules called microRNAs—small pieces of genetic material that can influence how genes behave. In experiments led by Roger Abounader, the researchers identified microRNAs that could interfere with the activity of several genes linked to glioblastoma’s development and growth.
Targeting more than one gene matters because cancer growth does not always depend on a single molecular switch. Multiple pathways may help cancer cells multiply and survive. In principle, microRNAs could suppress several tumor-related factors at once, rather than requiring a separate treatment for each one. The researchers note that drugs are not currently available for some of the molecules that contribute to cancer growth, making this approach worth investigating.
But targeting multiple genes does not mean the treatment is ready for use, or that it is certain to work in patients. Its effects depend on whether the molecules reach the intended tissue and how they act on cancer cells in a living body. The research is not about giving microRNAs on their own, either. It also tackles the problem of how to carry them across a barrier that normally blocks many substances from entering the brain.
Briefly Opening the Blood-Brain Barrier
To address the delivery problem, the team combined nanoparticles carrying microRNAs with focused ultrasound and tiny bubbles. Magnetic resonance imaging is used to guide the sound waves toward the area being targeted, helping focus the procedure on the intended site rather than directing it indiscriminately at the brain.
The tiny bubbles help open the blood-brain barrier for a short time when ultrasound is applied. This temporary change gives the nanoparticles an opportunity to pass into the brain, carrying the microRNAs with them. Once the cargo reaches the relevant area, the molecules can influence the activity of genes associated with tumor growth.
The approach therefore coordinates three elements: directing the sound waves to the right area, using the bubbles to allow limited and temporary passage across the barrier, and relying on nanoparticles to transport the genetic cargo. Each element has a distinct role. The sound waves do not carry the treatment themselves, the bubbles are not the gene-targeting material, and the nanoparticles serve as the delivery vehicle. Combining these steps is what makes delivery into the brain a central part of the experimental approach.
Temporarily opening the barrier remains a sensitive part of the method because the barrier serves an essential protective function. It is not enough to show that the cargo can reach the brain; further research must examine how to direct and use the approach safely and effectively. The published findings do not show that the technique is now an available treatment. They describe an experimental strategy that is still under study.
What Did the Experiments Show?
The researchers tested the method in laboratory experiments and animal models of glioblastoma. According to the team’s findings, microRNA treatment was associated with slower tumor growth, and the treated animals lived longer. These are encouraging early indicators, but on their own they do not answer important questions about whether the method can be used in people or how it might compare with established treatments.
There is a substantial gap between a result in an animal model and clinical success. The approach will need further study before it can be evaluated in treatment trials involving patients. The reported findings do not say that treatment in humans has begun, nor do they establish that the method can cure glioblastoma. The most accurate description is that the researchers have provided early evidence that genetic molecules can be combined with targeted opening of the blood-brain barrier—not that they have demonstrated a proven treatment for the disease.
Even so, the work raises an important research question: Can small genetic molecules silence several factors that support cancer, while also overcoming the obstacle that keeps them from reaching the brain? The team’s success in slowing tumor growth in animals gives that question an experimental basis, but it does not settle the matter. More studies are needed to determine whether the effects persist and can be reproduced in other tests, and whether the approach can eventually move on to clinical evaluation.
Who Led the Research, and What Are Its Limits?
The work was led by Roger Abounader, who holds both an MD and a PhD. He is a professor at the University of Virginia School of Medicine, in the departments of microbiology, immunology, and cancer biology. His work is also associated with the university’s Comprehensive Cancer Center and its Center for RNA Science and Medicine. The study was published in the Journal of Clinical Investigation, known as JCI, and the researchers made the full paper freely available.
The other researchers were Shekhar Saha, Ying Zhang, Myron K. Gilbert Jr., Colin Dove, Fareena Hanif, Elizabeth Qian Xu Mulhall, Silvia Bednarek, Yunan Sun, Pawel Marcinkiewicz, Xintao Wang, Jeong Kwak, Ahsan H. Bukhari, Haolin Li, Cady Hudson, Manikarana Dinda, Tapas Saha, Matthew McCord, Fedela de Jesus, Nicola Krushanks, Rosemar Rivera Colon, Lily Del Olio, Rajitha Anbu, Wenge Liu, Sunghee Choi, Benjamin Kivas, Pankaj Kumar, Alexander L. Klibanov, David Schiff, Jungsoo Suk, Justin Hanes, Jamie Mata, and Markus Hafner, along with Abounader.
Core funding came from the National Cancer Institute, part of the National Institutes of Health, through grants U01 CA220841 and P30 CA044579, and from the National Institute of Neurological Disorders and Stroke through grants R01 NS122222 and R21 NS122136. The team also received support from a pilot grant from the University of Virginia Comprehensive Cancer Center, a Shield grant, the Ben and Catherine Ivy Foundation, and the Focused Ultrasound Foundation. The researchers reported that they had no financial interest in the work.
The study is part of wider efforts at the University of Virginia to develop the use of focused ultrasound in cancer research. The university has worked with the Focused Ultrasound Foundation, based in Charlottesville, to establish a center dedicated to studying how the technology might be combined with cancer immunotherapy. The university’s Comprehensive Cancer Center is one of 57 centers in the United States with this designation from the National Cancer Institute. This broader context does not change the status of the current glioblastoma findings: the research remains experimental and has not demonstrated a benefit for patients.
The Bottom Line
This work outlines a research strategy that pairs efforts to target several genes with a way to carry treatment into the brain across its protective barrier. The University of Virginia team delivered microRNAs in nanoparticles and used focused ultrasound with tiny bubbles to allow temporary passage into the brain. In laboratory and animal experiments, the approach slowed glioblastoma growth and extended the animals’ lives. These findings are an early step, not a finished treatment: the method has not been shown to work in people and needs further study before it can be tested as a therapy for patients. The research offers a promising direction for tackling two challenges at once—the many factors that help a tumor grow and the difficulty of getting treatment into the brain.